CA3059265A1 - Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds - Google Patents

Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds Download PDF

Info

Publication number
CA3059265A1
CA3059265A1 CA3059265A CA3059265A CA3059265A1 CA 3059265 A1 CA3059265 A1 CA 3059265A1 CA 3059265 A CA3059265 A CA 3059265A CA 3059265 A CA3059265 A CA 3059265A CA 3059265 A1 CA3059265 A1 CA 3059265A1
Authority
CA
Canada
Prior art keywords
fucosyllactose
subject
compound
day
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3059265A
Other languages
English (en)
French (fr)
Inventor
Ardythe L. Morrow
Lee A. Denson
David S. Newburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of CA3059265A1 publication Critical patent/CA3059265A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3059265A 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds Pending CA3059265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482840P 2017-04-07 2017-04-07
US62/482,840 2017-04-07
PCT/US2018/026631 WO2018187792A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Publications (1)

Publication Number Publication Date
CA3059265A1 true CA3059265A1 (en) 2018-10-11

Family

ID=63712677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3059265A Pending CA3059265A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Country Status (8)

Country Link
US (2) US20200129534A1 (https=)
EP (1) EP3606535A4 (https=)
JP (3) JP2020513014A (https=)
CN (1) CN110730665A (https=)
AU (2) AU2018250337B2 (https=)
BR (1) BR112019020911A2 (https=)
CA (1) CA3059265A1 (https=)
WO (1) WO2018187792A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
EP3716984B1 (en) 2017-11-30 2024-03-20 Glycom A/S Mixture of hmos for treating wheat sensitivity
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
BE1027078A9 (nl) 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
JP2023501111A (ja) * 2019-11-14 2023-01-18 グリコム・アクティーゼルスカブ 腸管における胆汁酸プロファイルを均衡させるための合成組成物
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
WO2022122721A1 (en) * 2020-12-11 2022-06-16 Dsm Ip Assets B.V. Improved prebiotic formulations
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
US20260000713A1 (en) * 2021-12-01 2026-01-01 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
CN119842563B (zh) * 2025-03-17 2025-06-06 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651067T3 (es) * 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
US9200091B2 (en) * 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
CN104507483A (zh) * 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
EP2687845A1 (en) * 2012-07-20 2014-01-22 Nestec S.A. Fucose as a biomarker for gut immunity
EP3212198B1 (en) * 2014-10-29 2020-12-23 Glycom A/S Synthetic composition and method for promoting mucosal healing
HK1245658A1 (zh) * 2015-01-23 2018-08-31 Société des Produits Nestlé S.A. 可用於治疗ibd患者的营养组合物
PT3071235T (pt) * 2015-01-26 2018-02-21 Kaleido Biosciences Inc Produtos terapêuticos de glicanos e respetivos métodos relacionados
ES2886951T3 (es) * 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota

Also Published As

Publication number Publication date
US20200129534A1 (en) 2020-04-30
AU2024203194A1 (en) 2024-05-30
US20220133758A1 (en) 2022-05-05
JP2020513014A (ja) 2020-04-30
JP2025041753A (ja) 2025-03-26
AU2018250337A1 (en) 2019-10-24
CN110730665A (zh) 2020-01-24
EP3606535A1 (en) 2020-02-12
BR112019020911A2 (pt) 2020-05-12
EP3606535A4 (en) 2020-12-16
JP2023052629A (ja) 2023-04-11
WO2018187792A1 (en) 2018-10-11
AU2018250337B2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
CA3059265A1 (en) Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
Chen et al. The role of butyrate in attenuating pathobiont-induced hyperinflammation
JP2020513014A5 (https=)
Sun et al. Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism
Niu et al. Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases
Wędrychowicz et al. Advances in nutritional therapy in inflammatory bowel diseases
Chen et al. Fuzhuan brick tea polysaccharides attenuate metabolic syndrome in high-fat diet induced mice in association with modulation in the gut microbiota
Jiang et al. Mediation of the microbiome-gut axis by oyster (Crassostrea gigas) polysaccharides: A possible protective role in alcoholic liver injury
Prantera et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease
Wu et al. Chitosan alleviated menopausal symptoms and modulated the gut microbiota in estrogen-deficient rats
Liu et al. The effects and significance of gut microbiota and its metabolites on the regulation of osteoarthritis: Close coordination of gut-bone axis
Yang et al. Astragalus polysaccharides-induced gut microbiota play a predominant role in enhancing of intestinal barrier function of broiler chickens
Rotrekl et al. Composites of yeast glucan particles and curcumin lead to improvement of dextran sulfate sodium-induced acute bowel inflammation in rats
Dai et al. Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice
Rehman et al. Morchella esculenta polysaccharide attenuate obesity, inflammation and modulate gut microbiota
Zeng et al. Ameliorative effect of Saccharomyces cerevisiae JKSP39 on fusobacterium nucleatum and dextran sulfate sodium-induced colitis mouse model
CN105394768A (zh) 火龙果酵素营养液及其制备方法
Lv et al. Hepatoprotective effects of magnolol in fatty liver hemorrhagic syndrome hens through shaping gut microbiota and tryptophan metabolic profile
US20170258820A1 (en) Synthetic composition and method for promoting mucosal healing
Feng et al. The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: a review
Kim et al. Ameliorating effect of 2′-fucosyllactose and 6′-sialyllactose on lipopolysaccharide-induced intestinal inflammation
EP3866615B1 (en) Dietary supplement for treating dysbiosis
Zhang et al. Auricularia auricula polysaccharides exert anti-inflammatory effects in hepatic fibrosis by the gut–liver axis and enhancing SCFA metabolism
Mishra et al. Physiological benefits of Akkermansia muciniphila under high-altitude hypoxia
Zimmermann et al. Consumption of yeast-fermented wheat and rye breads increases colitis and mortality in a mouse model of colitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240717

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250708

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251110